• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
Truveta Tru, a research assistant powered by generative AI, now in Truveta Studio

Truveta Tru, a research assistant powered by generative AI, now in Truveta Studio

by Truveta News | Oct 28, 2024 | News

We are excited to share our latest AI innovation – Truveta Tru, Truveta Studio’s research assistant powered by generative AI. Trained on the Truveta Language Model (TLM) and Truveta Data, Tru enables researchers to accelerate their research in Truveta Studio using...
Healthcare AI: Earning trust and adoption by the research community

Healthcare AI: Earning trust and adoption by the research community

by Jay Nanduri | Oct 28, 2024 | Technology

In the journey toward advancing healthcare research, trust in AI tools is essential. Truveta is committed to not only delivering powerful AI-driven data insights but also ensuring transparency, quality, and speed for researchers. A significant part of this commitment...
Real-time monitoring of respiratory virus-associated hospitalizations: Trends through early October 2024

Real-time monitoring of respiratory virus-associated hospitalizations: Trends through early October 2024

by Truveta staff | Oct 28, 2024 | Research

Overall, the rate of hospitalizations associated with respiratory viruses decreased throughout September 2024 and into the first week of October. For infants and children aged 0-4 years old, respiratory virus-associated hospitalizations increased slightly by 2.9%...

Share this


Recent posts

  • Real-world survival outcomes for CRT and CCM therapies align with landmark trials
  • Understanding the potential impact of the upcoming ACIP vote on thimerosal-containing influenza vaccines
  • Biosimilar use is on the rise – but 1 in 8 patients return to Humira

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.AcceptPrivacy notice